Do polypills lead to neglect of lifestyle risk factors? Findings from an individual participant data meta-analysis among 3140 patients at high risk of cardiovascular disease

European Journal of Preventive Cardiology

Volumn 23, Issue 13, 2016, Pages 1393-1400

  Selak, Vanessa ^a   Bullen, Chris ^a   Stepien, Sandrine ^b   Arroll, Bruce ^a   Bots, Michiel ^c   Bramley, Dale ^d   Cass, Alan ^e   Grobbee, Diederick ^c   Hillis, Graham S ^f   Molanus, Barbara ^g   Neal, Bruce ^b   Patel, Anushka ^b   Rafter, Natasha ^a,h   Rodgers, Anthony ^b   Thom, Simon ⁱ   Tonkin, Andrew ^j   Usherwood, Tim ^b   Wadham, Angela ^a   Webster, Ruth ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d WAITEMATA DISTRICT HEALTH BOARD   (New Zealand)

^e MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^f ROYAL PERTH HOSPITAL   (Australia)

^g SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^h ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

ⁱ IMPERIAL COLLEGE LONDON   (United Kingdom)

^j MONASH UNIVERSITY   (Australia)

more..

Author keywords

fixed dose combination; lifestyle factors; meta analysis; Polypill; risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; HYDROCHLOROTHIAZIDE; LISINOPRIL; SIMVASTATIN; CARDIOVASCULAR AGENT;

ADULT; ANTHROPOMETRY; ANTIHYPERTENSIVE THERAPY; ARTICLE; AUSTRALIA; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; ENGLAND; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INDIA; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); MIDDLE AGED; NEGLECT; NETHERLANDS; NEW ZEALAND; PATIENT CARE; PHYSICAL ACTIVITY; PILL; POLYPILL; PRIORITY JOURNAL; RISK FACTOR; SELF REPORT; SMOKING; SMOKING CESSATION; WAIST CIRCUMFERENCE; DRUG COMBINATION; GLOBAL HEALTH; META ANALYSIS; MORBIDITY; PRIMARY PREVENTION; PROCEDURES; PSYCHOLOGY; TRENDS;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DRUG COMBINATIONS; GLOBAL HEALTH; HUMANS; LIFE STYLE; MORBIDITY; PRIMARY PREVENTION; RISK FACTORS;

EID: 84981516856     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487316638216     Document Type: Article

References (28)

1. Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): A prospective epidemiological survey. Lancet 2011; 378: 1231-1243.
2. World Health Organization. Secondary prevention of non-communicable disease in low and middle income countries through community-based and health service interventions-Wellcome Trust meeting report 1-3 August 2001, Geneva: World Health Organization, 2002.
3. Webster R, Patel A, Selak V, et al. Effectiveness of fixed dose combination medication ('polypills') compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries. Int J Cardiol 2015; 205: 147-156.
4. Castellano JM, Sanz G, Fernandez Oritz A, et al. A polypill strategy to improve global secondary cardiovascular prevention. From concept to reality. J Am Coll Cardiol 2014; 64: 613-621.
5. Huffman MD,. The polypill: From promise to pragmatism. PLoS Med 2015; 12: e1001862-e1001862.
6. Working Group on the Summit on Combination Therapy for CVD. Combination pharmacotherapy to prevent cardiovascular disease: Present status and challenges. Eur Heart J 2014; 35: 353-364.
7. Lonn E, Bosch J, Teo KK, et al. The polypill in the prevention of cardiovascular disease: Key concepts, current status, challenges, and future directions. Circulation 2010; 122: 2078-2088.
8. Tyson MJ,. Also dumfounded. Br Med J 2003; 326: 1419-1419.
9. Richens J, Imrie J, Copas A,. Condoms and seat belts: The parallels and the lessons. Lancet 2000; 355: 400-403.
10. Carlos S, de Irala J, Hanley M, et al. The use of expensive technologies instead of simple, sound and effective lifestyle interventions: A perpetual delusion. J Epidemiol Community Health 2014; 68: 897-904.
11. Webster R, Patel A, Billot L, et al. Prospective meta-analysis of trials comparing fixed dose combination based care with usual care in individuals at high cardiovascular risk: The SPACE Collaboration. Int J Cardiol 2013; 170: 30-35.
12. Selak V, Elley CR, Bullen C, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: Randomised controlled trial in primary care. Br Med J 2014; 348: g3318-g3318.
13. Patel A, Cass A, Peiris D, et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol 2015; 22: 920-930.
14. Thom S, Poulter N, Field J, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: The UMPIRE randomized clinical trial. JAMA 2013; 310: 918-929.
15. Selak V, Elley C, Crengle S, et al. Improving adherence using combination therapy (IMPACT): Design and protocol of a randomised controlled trial in primary care. Contemp Clin Trials 2011; 32: 909-915.
16. Liu H, Patel A, Brown A, et al. Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: A randomised controlled trial of a polypill-based strategy amongst Indigenous and non Indigenous people at high cardiovascular risk. BMC Public Health 2010; 10: 458-458.
17. Thom S, Field J, Poulter NR, et al. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): Rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe. Eur J Prev Cardiol 2014; 21: 252-261.
18. New Zealand Guidelines Group. New Zealand cardiovascular guidelines handbook: A summary resource for primary care practitioners, 2nd ed. Wellington: New Zealand Guidelines Group, 2005.
19. Debray TP, Moons KGM, Abo-Zaid GM, et al. Individual participant data meta-analysis for a binary outcome: One-stage or two stage? PLoS One 2013; 8: e60650-e60650.
20. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand. Reducing risk in heart disease: An expert guide to clinical practice for secondary prevention or coronary heart disease, Melbourne: National Heart Foundation of Australia, 2012.
21. National Stroke Foundation. Clinical guidelines for stroke management, Melbourne: National Stroke Foundation, 2010.
22. Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur J Prev Cardiol 2012; 19: 585-667.
23. Smith SC, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 Update: A guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124: 2458-2473.
24. National Vascular Disease Prevention Alliance. Guidelines for the management of absolute cardiovascular disease risk, Melbourne: National Stroke Foundation, 2012.
25. Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129: S49-S73.
26. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129: S1-S45.
27. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults. Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507-520.
28. World Health Organization. Prevention of cardiovascular disease: Guidelines for assessment and management of total cardiovascular risk, Geneva: World Health Organization, 2007.